Enteropathy-associated T-cell lymphoma secondary prevention: Difference between revisions

	Enteropathy-associated T-cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Enteropathy-associated T-cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Enteropathy-associated T-cell lymphoma secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Enteropathy-associated T-cell lymphoma secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Enteropathy-associated T-cell lymphoma secondary prevention
CDC on Enteropathy-associated T-cell lymphoma secondary prevention
Enteropathy-associated T-cell lymphoma secondary prevention in the news
Blogs on Enteropathy-associated T-cell lymphoma secondary prevention
Risk calculators and risk factors for Enteropathy-associated T-cell lymphoma secondary prevention

← Older edit

VisualWikitext

Latest revision as of 13:13, 8 March 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]

Overview

There are no established measures for the secondary prevention of enteropathy-associated T cell lymphoma.

Secondary Prevention

There are no established measures for the secondary prevention of enteropathy-associated T cell lymphoma.

References

Template:WikiDoc Sources

@@ Line 1: / Line 1: @@
+__NOTOC__
+{{Enteropathy-associated T-cell lymphoma}}
+{{CMG}} {{AE}}{{Nnasiri}}
 ==Overview==
-Enteropathy-associated T-cell Lymphoma (EATL), also enteropathy-type T-cell lymphoma (ETTL), is a type of T-cell non-hodgkin lymphoma that affects the small intestine, it is composed of large lymphoid cells. Enteropathy-associated T-cell lymphoma has two subtypes, type I enteropathy-associated T-cell lymphoma which has a strong association with celiac disease and it is more common in western countries and type II enteropathy-associated T-cell lymphoma which is mostly found among the Asian population. Genes involved in the pathogenesis of this disease include 8q24, T-cell receptor (TCR) beta and gamma, and 16q genes. On gross pathology, multiple intestinal ulcers are characteristic findings of EATL. On microscopic histopathological analysis, monotonous cells, round or angulated vesicular nuclei, and prominent nucleoli are characteristic findings of enteropathy-associated T-cell lymphoma. There are no established causes for enteropathy-associated T-cell lymphoma. EATL must be differentiated from other diseases such as peptic ulcer, poorly-differentiated adenocarcinoma, MALT lymphoma, diffuse large B cell lymphoma, and mantle cell lymphoma.
+There are no established measures for the secondary prevention of enteropathy-associated T cell lymphoma.
 ==Secondary Prevention==
-There are no established measures for the secondary prevention of enteropathy-associated T cell lymphoma.
+*There are no established measures for the secondary prevention of enteropathy-associated T cell lymphoma.
 ==References==
 {{reflist|2}}

Enteropathy-associated T-cell lymphoma secondary prevention: Difference between revisions

Latest revision as of 13:13, 8 March 2019

Overview

Secondary Prevention

References

Navigation menu

Search